Literature DB >> 7757993

Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences.

F Pedeutour1, M P Simon, F Minoletti, G Sozzi, M A Pierotti, F Hecht, C Turc-Carel.   

Abstract

Ring chromosomes have been found with some regularity as solid tumors have come increasingly under cytogenetic study. The full genetic content and significance of these rings remain unclear. Dermatofibrosarcoma protuberans, a tumor of the deep dermis, consistently has supernumerary ring chromosomes, sometimes as the sole detectable cytogenetic change. Using a modified method for comparative genomic hybridization and fluorescent in situ hybridization with a panel of various probes, we found that these ring chromosomes consistently contain the chromosome 22 centromere along with interstitial sequences from chromosomes 17 and 22, specifically from regions 17q23-24 and 22q11-12. The ring chromosomes in dermatofibrosarcoma protuberans are vehicles for a particular pattern of relatively low-level genomic amplification of selected sequences.

Entities:  

Mesh:

Year:  1995        PMID: 7757993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans.

Authors:  J Wang; Y Morimitsu; S Okamoto; M Hisaoka; T Ishida; W Sheng; H Hashimoto
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

Review 2.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

3.  Extragnathic fibromyxoma of bone versus inflammatory myofibroblastic tumor.

Authors:  M T Flores-Corral; C Ballestin; M A Martínez-Gonzalez; F J Martínez-Tello
Journal:  Skeletal Radiol       Date:  1998-08       Impact factor: 2.199

4.  Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22).

Authors:  Jad Saab; Ian M Rosenthal; Lu Wang; Klaus J Busam; Kishwer S Nehal; Mark A Dickson; Meera R Hameed; Travis J Hollmann
Journal:  Am J Dermatopathol       Date:  2017-04       Impact factor: 1.533

5.  CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

Authors:  Grant Eilers; Jeffrey T Czaplinski; Mark Mayeda; Nacef Bahri; Derrick Tao; Meijun Zhu; Jason L Hornick; Neal I Lindeman; Ewa Sicinska; Andrew J Wagner; Jonathan A Fletcher; Adrian Mariño-Enriquez
Journal:  Mol Cancer Ther       Date:  2015-04-07       Impact factor: 6.261

6.  Dermatofibrosarcoma protuberans: Our experience of 59 cases.

Authors:  Alessio Stivala; Giuseppe A G Lombardo; Gianluca Pompili; Maria Stella Tarico; Filippo Fraggetta; Rosario Emanuele Perrotta
Journal:  Oncol Lett       Date:  2012-08-30       Impact factor: 2.967

7.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Authors:  Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

8.  Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans.

Authors:  Marie Karanian; Gaëlle Pérot; Jean-Michel Coindre; Frédéric Chibon; Florence Pedeutour; Agnès Neuville
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

9.  Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22.

Authors:  R Naeem; M L Lux; S F Huang; S P Naber; J M Corson; J A Fletcher
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

10.  Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans.

Authors:  Piotr Rutkowski; Agnieszka Wozniak; Tomasz Switaj
Journal:  Sarcoma       Date:  2011-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.